Suppr超能文献

组蛋白、血小板因子 4 和肝素类物质对蛋白 C 激活的调节:对活化蛋白 C 形成的新认识。

Modulation of protein C activation by histones, platelet factor 4, and heparinoids: new insights into activated protein C formation.

机构信息

From the Department of Pediatrics, The Children's Hospital of Philadelphia, PA (M.A.K., G.Z., L.Z., G.D., S.K., M.P.); ParinGenix, Weston, FL (S.M.); and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA (SK., M.P.).

出版信息

Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):120-6. doi: 10.1161/ATVBAHA.113.302236. Epub 2013 Oct 31.

Abstract

OBJECTIVE

Histones are detrimental in late sepsis. Both activated protein C (aPC) and heparin can reverse their effect. Here, we investigated whether histones can modulate aPC generation in a manner similar to another positively charged molecule, platelet factor 4, and how heparinoids (unfractionated heparin or oxygen-desulfated unfractionated heparin with marked decrease anticoagulant activity) may modulate this effect.

APPROACH AND RESULTS

We measured in vitro and in vivo effects of histones, platelet factor 4, and heparinoids on aPC formation, activated partial thromboplastin time, and murine survival. In vitro, histones and platelet factor 4 both affect thrombin/thrombomodulin aPC generation following a bell-shaped curve, with a peak of >5-fold enhancement. Heparinoids shift these curves rightward. Murine aPC generation studies after infusions of histones, platelet factor 4, and heparinoids supported the in vitro data. Importantly, although unfractionated heparin and 2-O, 3-O desulfated heparin both reversed the lethality of high-dose histone infusions, only mice treated with 2-O, 3-O desulfated heparin demonstrated corrected activated partial thromboplastin times and had significant levels of aPC.

CONCLUSIONS

Our data provide a new contextual model of how histones affect aPC generation, and how heparinoid therapy may be beneficial in sepsis. These studies provide new insights into the complex interactions controlling aPC formation and suggest a novel therapeutic interventional strategy.

摘要

目的

组蛋白在晚期败血症中是有害的。活化蛋白 C(aPC)和肝素都可以逆转其作用。在这里,我们研究了组蛋白是否可以以类似于另一种带正电荷的分子血小板因子 4 的方式调节 aPC 的产生,以及肝素类物质(未分级肝素或抗凝活性显著降低的去氧硫酸化未分级肝素)如何调节这种作用。

方法和结果

我们测量了组蛋白、血小板因子 4 和肝素类物质对 aPC 形成、活化部分凝血活酶时间和小鼠存活的体外和体内影响。在体外,组蛋白和血小板因子 4 都以钟形曲线的形式影响凝血酶/血栓调节蛋白 aPC 的产生,增强幅度超过 5 倍。肝素类物质使这些曲线向右移动。组蛋白、血小板因子 4 和肝素类物质输注后小鼠 aPC 生成研究支持了体外数据。重要的是,尽管未分级肝素和 2-O、3-O 去硫酸肝素都逆转了高剂量组蛋白输注的致死性,但只有用 2-O、3-O 去硫酸肝素治疗的小鼠才显示出纠正的活化部分凝血活酶时间和显著水平的 aPC。

结论

我们的数据提供了一个新的背景模型,说明组蛋白如何影响 aPC 的产生,以及肝素类药物治疗在败血症中的可能益处。这些研究为控制 aPC 形成的复杂相互作用提供了新的见解,并提出了一种新的治疗干预策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验